TABLE 2.
Comparative incidence of major bleeding for patients receiving various oral anticoagulants and OCS burst cotherapy in the cohort study.
| Major bleeding | Person‐years | Adjusted incidence/1000 person‐years (95% CI) | |
|---|---|---|---|
| Edoxaban + OCS burst | 166 | 5342 | 30.36 (26.03–35.40) |
| Apixaban + OCS burst | 202 | 5771 | 34.93 (30.45–40.08) |
| Dabigatran + OCS burst | 319 | 7550 | 42.47 (38.05–47.40) |
| Rivaroxaban + OCS burst | 566 | 12,104 | 46.99 (43.29–51.01) |
| Warfarin + OCS burst | 1198 | 15,417 | 67.30 (63.31–71.54) |
| RD (95% CI) | IRR (95% CI) a | ||
| Edoxaban + OCS burst vs. | |||
| Apixaban + OCS burst | −4.58 (−11.27 to 2.12) | 0.87 (0.71 to 1.07) | |
| Dabigatran + OCS burst | −12.11 (−18.71 to −5.51) | 0.71 (0.59 to 0.86) | |
| Rivaroxaban + OCS burst | −16.64 (−22.69 to −10.58) | 0.65 (0.54 to 0.77) | |
| Warfarin + OCS burst | −36.94 (−43.17 to −30.72) | 0.45 (0.38 to 0.53) | |
| Apixaban + OCS burst vs. | |||
| Dabigatran + OCS burst | −7.54 (−14.23 to −0.84) | 0.82 (0.69 to 0.98) | |
| Rivaroxaban + OCS burst | −12.06 (−18.22 to −5.90) | 0.74 (0.63 to 0.87) | |
| Warfarin + OCS burst | −32.37 (−38.69 to −26.05) | 0.52 (0.45 to 0.60) | |
| Dabigatran + OCS burst vs. | |||
| Rivaroxaban + OCS burst | −4.52 (−10.58 to 1.53) | 0.90 (0.79 to 1.04) | |
| Warfarin + OCS burst | −24.83 (−31.05 to −18.61) | 0.63 (0.56 to 0.72) | |
| Rivaroxaban + OCS burst vs. | |||
| Warfarin + OCS burst | −20.31 (−25.95 to −14.67) | 0.70 (0.63 to 0.77) | |
Note: The bold values indicate statistical significance (p‐value less than 0.05).
Abbreviations: CI, confidence interval; IRR, incidence risk ratio; OCS, oral corticosteroid; RD, risk difference.
Model was adjusted by overlap weighting using the propensity score for age, sex, residence, income level, Charlson comorbidity index score, myocardial infarction, congestive heart failure, peripheral vascular disease, stroke, transient ischemic attack, dementia, chronic pulmonary disease, anemia, kidney diseases, hepatic diseases, hypertension, bleeding history, alcohol use, number of outpatient visits, non‐steroidal anti‐inflammatory drugs, proton pump inhibitors, antihypertensives, clopidogrel, ticlopidine, insulin, oral hypoglycemic agents, and lipid lowering agents.